Some Sanofi plant workers having to self-quarantine, CEO says by Eric Sagonowsky Friday, April 3, 2020 Sanofi, a hydroxychloroquine maker, is producing as much as it can amid the pandemic, but some workers are having to exit the line manufacturing line.
Coronavirus tracker: U.K. government plans major COVID-19 trial by Eric Sagonowsky, Kyle Blankenship, Angus Liu, Conor Hale Friday, April 3, 2020 The U.K. government plans to enroll the world's largest clinical trial to treat COVID-19, but its health department is warning it might take time.
Unlike U.S., Europe limits chloroquine to COVID-19 trials by Eric Sagonowsky Thursday, April 2, 2020 While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.
Gilead stuck owing $752M for stepping on CAR-T patent by Eric Sagonowsky Wednesday, April 1, 2020 Gilead failed to persuade a judge to overturn a $752 million CAR-T patent verdict, and the company could face bigger damages down the line.
What to expect from the COVID-19 vaccine race? Experts weigh in by Eric Sagonowsky Tuesday, March 31, 2020 Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.
Lundbeck aims to grow Vyepti in busy migraine prevention field by Eric Sagonowsky Tuesday, March 31, 2020 Despite its CGRP rivals having a head start, Lundbeck is confident it can succeed with Vyepti, an exec said.
Without data, FDA gives chloroquine emergency approval by Eric Sagonowsky Monday, March 30, 2020 A drumbeat of anecdotal evidence and high-level praise for hydroxychloroquine in patients with COVID-19 spurred the FDA to grant an emergency nod.
Congress' stimulus likely pushes back drug pricing action by Eric Sagonowsky Monday, March 30, 2020 Congress' massive coronavirus stimulus likely pushes back any drug pricing action until after the election.
Experts float Roche's Activase as potential COVID-19 therapy by Eric Sagonowsky Friday, March 27, 2020 Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.
Intercept's closely watched NASH drug hits a COVID-19 snag by Eric Sagonowsky Friday, March 27, 2020 Amid the coronavirus pandemic, the FDA delayed an advisory committee hearing to review Intercept's liver drug obeticholic acid as a NASH treatment.
